

Company Announcement

Compumedics Limited

Cleansing Notice

This notice is given by Compumedics Limited (Compumedics) under section 708A(5)(e) and 708A(6) of the *Corporations Act 2001* (the Act).

On 26th September 2016, Compumedics issued to Australian institutional investors 8,333,333 fully paid ordinary shares (ASX Code: CMP) (the Shares) at AU\$0.54 per share.

The Shares are in a class of securities that were quoted on the Australian Securities Exchange at all times in the last three months before the date on which they were issued.

Compumedics gives notice pursuant to section 708A(5)(e) of the Act in connection with the shares referred to above.

Compumedics issued the shares without disclosure to the investors under Part 6D.2 of the Act.

As at the date of this notice, Compumedics has complied with:

- the provisions of Chapter 2M of the Act as they apply to Compumedics; and
- 2 section 674 of the Act.

As at the date of this notice, there is no excluded information as described in section 708A(7) and (8) of the Act.

Dated: 30 September 2016

David LawsonCompany Secretary



Compumedics Limited [ASX: CMP] is a medical device company involved in the development, manufacture and commercialisation of diagnostics technology for the sleep, brain and ultrasonic blood-flow monitoring applications. The company owns US based Neuroscan and Germany based DWL Elektronishe GmbH. In conjunction with these two subsidiaries, Compumedics has a broad international reach, including the Americas, Australia and Asia Pacific, Europe and the Middle East.

Executive Chairman Dr David Burton founded Compumedics in 1987. In the same year the company successfully designed and installed the first Australian, fully computerised sleep clinic at Epworth Hospital in Melbourne. Following this early success, Compumedics focused on the development of products that sold into the growing international sleep clinic and home monitoring markets.

Compumedics listed on the Australian Securities Exchange in 2000. Over the years, Compumedics has received numerous awards, including Australia's Exporter of the Year, and has been recognised as a Top 100 Innovator by both German and Australian governments.

For further information please contact:

Dr David Burton
Executive Chairman, CEO Executive Director

Phone: + 61 3 8420 7300 Fax: +61 3 8420 7399

David Lawson
Director and Chief Financial Officer

Phone: + 61 3 8420 7300 Fax: +61 3 8420 7399

Investor Relations, Media & PR enquires:

Rod North
Managing Director
Bourse Communications Pty Ltd
Phone: +61 3 9510 8309

Mobile: 0408 670 706

Richard Allen
Oxygen Financial PR
Ph: + 61 3 9915 6341
Mob: 0403 493 049